Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23, 469

James R. Hayes, Ellen A. Rorke, David W. Robertson, Benita S Katzenellenbogen, John A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

Previous studies from this laboratory have revealed that two potent nonsteroidal antiestrogens, CI628 [α-(p-(2-(1-pyrrolidino)ethoxy)phenyl)4-methoxy-α′-nitrostilbene] and U23, 469 [cis-(3-(p-(l, 2, 3, 4-tetrahydro-6-methoxy-2-phenyll-naphthyl)phenoxy)1, 2-propanediol], are metabolized during their action in vivo to more polar metabolites. We have identified these metabolites as the demethylated forms of the parentantiestrogen and have synthesized them (CI628M and U23.469M). In studies reported here, we compare the potency of the metabolites and parent antiestrogens in terms of their 1) affinity for cytoplasmic estrogen receptor, 2) ability to translocate estrogen receptor to the nuclear fraction in whole uteri in organ culture in vitro and to prevent nuclear uptake of [3H]estradiol, 3) ability to prevent estradiol stimulation of induced protein synthesis in vitro, and 4) ability to inhibit estradiol stimulation of uterine weight gain and peroxidase activity in vivo. The antiestrogens compete with [3H]estradiol for binding to cytosol estrogen receptor with the following affinities: CI628M, 135%; U23.469M, 30%; CI628, 11%; and U23.469, 0.1%, where estradiol affinity is considered 100%. In whole uteri in vitro, all four compounds deplete cytoplasmic receptor and translocate estrogen receptor into the nucleus, and they prevent nuclear localization of [3H]estradiol and inhibit estradiol stimulation of induced protein synthesis in a dose-related fashion; CI628M and U23.469M are more potent, being as effective as their parent compounds at 10- to 100-fold lower doses. In 3-day in vivo assays, dose-response curves indicate that the metabolites and parent compounds are equally potent in inhibiting estradiol-stimulated uterine weight gain and peroxidase activity. These studies document that the demethylated metabolites of the antiestrogens have a higher affinity for receptor and a greater biological potency in vitro. However, in vivo, where the parent compounds are rapidly and efficiently converted to the metabolites, both forms have comparable potencies.

Original languageEnglish (US)
Pages (from-to)164-172
Number of pages9
JournalEndocrinology
Volume108
Issue number1
DOIs
StatePublished - Jan 1981

Fingerprint

Nitromifene
Estrogen Receptor Modulators
Estrogen Receptors
Estradiol
Cytoplasmic and Nuclear Receptors
Peroxidase
Weight Gain
Uterus
Estrogen Receptor beta
Propylene Glycol
ovothiol A
Organ Culture Techniques
Cytosol
Proteins

ASJC Scopus subject areas

  • Endocrinology

Cite this

Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23, 469. / Hayes, James R.; Rorke, Ellen A.; Robertson, David W.; Katzenellenbogen, Benita S; Katzenellenbogen, John A.

In: Endocrinology, Vol. 108, No. 1, 01.1981, p. 164-172.

Research output: Contribution to journalArticle

Hayes, James R. ; Rorke, Ellen A. ; Robertson, David W. ; Katzenellenbogen, Benita S ; Katzenellenbogen, John A. / Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23, 469. In: Endocrinology. 1981 ; Vol. 108, No. 1. pp. 164-172.
@article{5c7b28e8c8cd48f39448f0b064cb2390,
title = "Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23, 469",
abstract = "Previous studies from this laboratory have revealed that two potent nonsteroidal antiestrogens, CI628 [α-(p-(2-(1-pyrrolidino)ethoxy)phenyl)4-methoxy-α′-nitrostilbene] and U23, 469 [cis-(3-(p-(l, 2, 3, 4-tetrahydro-6-methoxy-2-phenyll-naphthyl)phenoxy)1, 2-propanediol], are metabolized during their action in vivo to more polar metabolites. We have identified these metabolites as the demethylated forms of the parentantiestrogen and have synthesized them (CI628M and U23.469M). In studies reported here, we compare the potency of the metabolites and parent antiestrogens in terms of their 1) affinity for cytoplasmic estrogen receptor, 2) ability to translocate estrogen receptor to the nuclear fraction in whole uteri in organ culture in vitro and to prevent nuclear uptake of [3H]estradiol, 3) ability to prevent estradiol stimulation of induced protein synthesis in vitro, and 4) ability to inhibit estradiol stimulation of uterine weight gain and peroxidase activity in vivo. The antiestrogens compete with [3H]estradiol for binding to cytosol estrogen receptor with the following affinities: CI628M, 135{\%}; U23.469M, 30{\%}; CI628, 11{\%}; and U23.469, 0.1{\%}, where estradiol affinity is considered 100{\%}. In whole uteri in vitro, all four compounds deplete cytoplasmic receptor and translocate estrogen receptor into the nucleus, and they prevent nuclear localization of [3H]estradiol and inhibit estradiol stimulation of induced protein synthesis in a dose-related fashion; CI628M and U23.469M are more potent, being as effective as their parent compounds at 10- to 100-fold lower doses. In 3-day in vivo assays, dose-response curves indicate that the metabolites and parent compounds are equally potent in inhibiting estradiol-stimulated uterine weight gain and peroxidase activity. These studies document that the demethylated metabolites of the antiestrogens have a higher affinity for receptor and a greater biological potency in vitro. However, in vivo, where the parent compounds are rapidly and efficiently converted to the metabolites, both forms have comparable potencies.",
author = "Hayes, {James R.} and Rorke, {Ellen A.} and Robertson, {David W.} and Katzenellenbogen, {Benita S} and Katzenellenbogen, {John A.}",
year = "1981",
month = "1",
doi = "10.1210/endo-108-1-164",
language = "English (US)",
volume = "108",
pages = "164--172",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Biological Potency and Uterine Estrogen Receptor Interactions of the Metabolites of the Antiestrogens CI628 and U23, 469

AU - Hayes, James R.

AU - Rorke, Ellen A.

AU - Robertson, David W.

AU - Katzenellenbogen, Benita S

AU - Katzenellenbogen, John A.

PY - 1981/1

Y1 - 1981/1

N2 - Previous studies from this laboratory have revealed that two potent nonsteroidal antiestrogens, CI628 [α-(p-(2-(1-pyrrolidino)ethoxy)phenyl)4-methoxy-α′-nitrostilbene] and U23, 469 [cis-(3-(p-(l, 2, 3, 4-tetrahydro-6-methoxy-2-phenyll-naphthyl)phenoxy)1, 2-propanediol], are metabolized during their action in vivo to more polar metabolites. We have identified these metabolites as the demethylated forms of the parentantiestrogen and have synthesized them (CI628M and U23.469M). In studies reported here, we compare the potency of the metabolites and parent antiestrogens in terms of their 1) affinity for cytoplasmic estrogen receptor, 2) ability to translocate estrogen receptor to the nuclear fraction in whole uteri in organ culture in vitro and to prevent nuclear uptake of [3H]estradiol, 3) ability to prevent estradiol stimulation of induced protein synthesis in vitro, and 4) ability to inhibit estradiol stimulation of uterine weight gain and peroxidase activity in vivo. The antiestrogens compete with [3H]estradiol for binding to cytosol estrogen receptor with the following affinities: CI628M, 135%; U23.469M, 30%; CI628, 11%; and U23.469, 0.1%, where estradiol affinity is considered 100%. In whole uteri in vitro, all four compounds deplete cytoplasmic receptor and translocate estrogen receptor into the nucleus, and they prevent nuclear localization of [3H]estradiol and inhibit estradiol stimulation of induced protein synthesis in a dose-related fashion; CI628M and U23.469M are more potent, being as effective as their parent compounds at 10- to 100-fold lower doses. In 3-day in vivo assays, dose-response curves indicate that the metabolites and parent compounds are equally potent in inhibiting estradiol-stimulated uterine weight gain and peroxidase activity. These studies document that the demethylated metabolites of the antiestrogens have a higher affinity for receptor and a greater biological potency in vitro. However, in vivo, where the parent compounds are rapidly and efficiently converted to the metabolites, both forms have comparable potencies.

AB - Previous studies from this laboratory have revealed that two potent nonsteroidal antiestrogens, CI628 [α-(p-(2-(1-pyrrolidino)ethoxy)phenyl)4-methoxy-α′-nitrostilbene] and U23, 469 [cis-(3-(p-(l, 2, 3, 4-tetrahydro-6-methoxy-2-phenyll-naphthyl)phenoxy)1, 2-propanediol], are metabolized during their action in vivo to more polar metabolites. We have identified these metabolites as the demethylated forms of the parentantiestrogen and have synthesized them (CI628M and U23.469M). In studies reported here, we compare the potency of the metabolites and parent antiestrogens in terms of their 1) affinity for cytoplasmic estrogen receptor, 2) ability to translocate estrogen receptor to the nuclear fraction in whole uteri in organ culture in vitro and to prevent nuclear uptake of [3H]estradiol, 3) ability to prevent estradiol stimulation of induced protein synthesis in vitro, and 4) ability to inhibit estradiol stimulation of uterine weight gain and peroxidase activity in vivo. The antiestrogens compete with [3H]estradiol for binding to cytosol estrogen receptor with the following affinities: CI628M, 135%; U23.469M, 30%; CI628, 11%; and U23.469, 0.1%, where estradiol affinity is considered 100%. In whole uteri in vitro, all four compounds deplete cytoplasmic receptor and translocate estrogen receptor into the nucleus, and they prevent nuclear localization of [3H]estradiol and inhibit estradiol stimulation of induced protein synthesis in a dose-related fashion; CI628M and U23.469M are more potent, being as effective as their parent compounds at 10- to 100-fold lower doses. In 3-day in vivo assays, dose-response curves indicate that the metabolites and parent compounds are equally potent in inhibiting estradiol-stimulated uterine weight gain and peroxidase activity. These studies document that the demethylated metabolites of the antiestrogens have a higher affinity for receptor and a greater biological potency in vitro. However, in vivo, where the parent compounds are rapidly and efficiently converted to the metabolites, both forms have comparable potencies.

UR - http://www.scopus.com/inward/record.url?scp=0019379111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019379111&partnerID=8YFLogxK

U2 - 10.1210/endo-108-1-164

DO - 10.1210/endo-108-1-164

M3 - Article

C2 - 7007017

AN - SCOPUS:0019379111

VL - 108

SP - 164

EP - 172

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -